World Health Organization. Cardiovascular diseases (CVDs) Fact Sheet. 2017. Show
Benjamin, E. J. et al. Heart disease and stroke statistics–2017 update: a report from the American Heart Association. Circulation 136, e146–e603 (2017). Google Scholar Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol–United States, 1999–2002 and 2005–2008. MMWR Morb. Mortal. Wkly Rep. 60, 109–114 (2011). Google Scholar GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1545–1602 (2016). Article Google Scholar Herrington, W., Lacey, B., Sherliker, P., Armitage, J. & Lewington, S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ. Res. 118, 535–546 (2016). Article CAS PubMed Google Scholar Roth, G. A. et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 132, 1667–1678 (2015). Article PubMed Google Scholar WHO. Cardiovascular disease: Global Hearts Initiative. (World Health Organization, Geneva, 2018). Google Scholar Goldstein, J. L. & Brown, M. S. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161, 161–172 (2015). A telling of the cholesterol tale from two luminaries in the field. Article CAS PubMed PubMed Central Google Scholar Libby, P. The forgotten majority: unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46, 1225–1228 (2005). Article PubMed Google Scholar Hochholzer, W. & Giugliano, R. P. Lipid lowering goals: back to nature? Ther. Adv. Cardiovasc. Dis. 4, 185–191 (2010). CAS Google Scholar Giugliano, R. P. et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2, 547–555 (2017). Article PubMed PubMed Central Google Scholar Hopstock, L. A. et al. Longitudinal and secular trends in total cholesterol levels and impact of lipid-lowering drug use among Norwegian women and men born in 1905–1977 in the population-based Tromso study 1979–2016. BMJ Open. 7, e015001 (2017). Article PubMed PubMed Central Google Scholar Schreiner, P. J., Jacobs, D. R. Jr., Wong, N. D. & Kiefe, C. I. Twenty-five year secular trends in lipids and modifiable risk factors in a population-based biracial cohort: the Coronary Artery Risk Development in Young Adults (CARDIA) Study, 1985–2011. J. Am. Heart. Assoc. 5, e003384 (2016). Article PubMed PubMed Central Google Scholar Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38, 2459–2472 (2017). Article CAS PubMed PubMed Central Google Scholar Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478–3490 (2013). Article CAS PubMed PubMed Central Google Scholar Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006). Article CAS PubMed Google Scholar Miller, Y. I. et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108, 235–248 (2011). Article CAS PubMed PubMed Central Google Scholar Navab, M. et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 45, 993–1007 (2004). Article CAS PubMed Google Scholar Gistera, A. & Hansson, G. K. The immunology of atherosclerosis. Nat. Rev. Nephrol. 13, 368–380 (2017). Article PubMed CAS Google Scholar Libby, P., Hansson, G. K. & Lichtman, A. H. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38, 1092–1104 (2013). Article CAS PubMed PubMed Central Google Scholar Tardif, J. C. et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371, 1761–1768 (2008). Article CAS PubMed Google Scholar Ketelhuth, D. F. J. & Hansson, G. K. Adaptive response of T and B cells in atherosclerosis. Circ. Res. 118, 668–678 (2016). A summary of the roles of adaptive immunity in atherosclerosis. Article CAS PubMed Google Scholar Boren, J. & Williams, K. J. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr. Opin. Lipidol. 27, 473–483 (2016). Article CAS PubMed Google Scholar Llorente-Cortes, V., Martinez-Gonzalez, J. & Badimon, L. LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 20, 1572–1579 (2000). Article CAS PubMed Google Scholar Musunuru, K. & Kathiresan, S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ. Res. 118, 579–585 (2016). A window into novel aspects of lipids and atherosclerosis emerging from contemporary human genetics. Article CAS PubMed PubMed Central Google Scholar Libby, P. Triglycerides on the rise: should we swap seats on the seesaw? Eur. Heart J. 36, 774–776 (2015). Article PubMed Google Scholar Nordestgaard, B. G. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ. Res. 118, 547–563 (2016). A rethinking of the contributions of triglyceride-rich lipoproteins to human atherogenesis based on observational epidemiology and human genetics studies. Article CAS PubMed Google Scholar Burgess, S. et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 3, 619–627 (2018). Article PubMed PubMed Central Google Scholar Kranzhofer, R., Browatzki, M., Schmidt, J. & Kubler, W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem. Biophys. Res. Commun. 257, 826–828 (1999). Article CAS PubMed Google Scholar McMaster, W. G., Kirabo, A., Madhur, M. S. & Harrison, D. G. Inflammation, immunity, and hypertensive end-organ damage. Circ. Res. 116, 1022–1033 (2015). Article CAS PubMed PubMed Central Google Scholar Rocha, V. Z. & Libby, P. Obesity, inflammation, and atherosclerosis. Nat. Rev. Cardiol. 6, 399–409 (2009). Article CAS PubMed Google Scholar Despres, J. P. Body fat distribution and risk of cardiovascular disease: an update. Circulation 126, 1301–1313 (2012). Article PubMed Google Scholar Libby, P., Nahrendorf, M. & Swirski, F. K. Leukocytes link local and systemic inflammation in ischemic cardiovascular disease. J. Am. Coll. Cardiol. 67, 1091–1103 (2016). Article CAS PubMed PubMed Central Google Scholar Libby, P. et al. Inflammation, immunity, and infection in atherothrombosis: JACC Review Topic of the Week. J Am Coll Cardiol. 72, 2071–2081 (2018). Article CAS PubMed PubMed Central Google Scholar Ridker, P. M. A test in context: high-sensitivity C-reactive protein. J. Am. Coll. Cardiol. 67, 712–723 (2016). Article PubMed Google Scholar Nus, M. & Mallat, Z. Immune-mediated mechanisms of atherosclerosis and implications for the clinic. Expert Rev. Clin. Immunol. 12, 1217–1237 (2016). Article CAS PubMed Google Scholar Ignarro, L. J. & Napoli, C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr. Diab. Rep. 5, 17–23 (2005). Article CAS PubMed Google Scholar Cybulsky, M. I. & Gimbrone, M. A. Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251, 788–791 (1991). Article CAS PubMed Google Scholar Li, H., Cybulsky, M. I., Gimbrone, M. A. Jr. & Libby, P. An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule, in rabbit endothelium. Arterioscler. Thromb. 13, 197–204 (1993). Article PubMed Google Scholar SenBanerjee, S. et al. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J. Exp. Med. 199, 1305–1315 (2004). Article CAS PubMed PubMed Central Google Scholar Gimbrone, M. A. & García-Cardeña, G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ. Res. 118, 620–636 (2016). An up-to-date summary of the roles of endothelial cells in atherosclerosis from a pioneering investigator. Article CAS PubMed PubMed Central Google Scholar Chatzizisis, Y. S. et al. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J. Am. Coll. Cardiol. 49, 2379–2393 (2007). Article CAS PubMed Google Scholar Bennett, M. R., Sinha, S. & Owens, G. K. Vascular smooth muscle cells in atherosclerosis. Circ. Res. 118, 692–702 (2016). Article CAS PubMed PubMed Central Google Scholar Robbins, C. S. et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 19, 1166–1172 (2013). Article CAS PubMed PubMed Central Google Scholar Wanschel, A. et al. Neuroimmune guidance cue semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention. Arterioscler. Thromb. Vasc. Biol. 33, 886–93 (2013). Article CAS PubMed PubMed Central Google Scholar Swirski, F. K., Nahrendorf, M. & Libby, P. The ins and outs of inflammatory cells in atheromata. Cell. Metab. 15, 135–136 (2012). Article CAS PubMed Google Scholar Libby, P. & Hansson, G. K. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ. Res. 116, 307–311 (2015). Article CAS PubMed PubMed Central Google Scholar Gistera, A. et al. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci. Transl. Med. 5, 196ra100 (2013). Article PubMed CAS Google Scholar Grabner, R. et al. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J. Exp. Med. 206, 233–248 (2009). Article PubMed PubMed Central CAS Google Scholar Geng, Y.-J. & Libby, P. Evidence for apoptosis in advanced human atheroma. Co-localization with interleukin-1 beta-converting enzyme. Am. J. Pathol. 147, 251–266 (1995). CAS PubMed PubMed Central Google Scholar Clarke, M. C., Talib, S., Figg, N. L. & Bennett, M. R. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ. Res. 106, 363–372 (2010). Article CAS PubMed Google Scholar Tabas, I., Garcia-Cardena, G. & Owens, G. K. Recent insights into the cellular biology of atherosclerosis. J. Cell. Biol. 209, 13–22 (2015). Article CAS PubMed PubMed Central Google Scholar Yurdagul, A., Doran, A. C., Cai, B., Fredman, G. & Tabas, I. A. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front. Cardiovasc. Med. 8, 4–86 (2018). Google Scholar Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017). Article PubMed PubMed Central Google Scholar Fuster, J. J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017). Article CAS PubMed PubMed Central Google Scholar Wolach, O. et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci. Transl. Med. 10, eaan8292 (2018). Article PubMed PubMed Central CAS Google Scholar Libby, P. & Ebert, B. CHIP (clonal hematopoiesis of indeterminate potential): potent and newly recognized contributor to cardiovascular risk. Circulation 138, 666–668 (2018). Article PubMed PubMed Central Google Scholar Ruiz, J. L., Hutcheson, J. D. & Aikawa, E. Cardiovascular calcification: current controversies and novel concepts. Cardiovasc. Pathol. 24, 207–212 (2015). Article CAS PubMed Google Scholar Ruiz, J. L., Weinbaum, S., Aikawa, E. & Hutcheson, J. D. Zooming in on the genesis of atherosclerotic plaque microcalcifications. J. Physiol. 594, 2915–2927 (2016). Article CAS PubMed PubMed Central Google Scholar Huang, H. et al. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 103, 1051–1056 (2001). Article CAS PubMed Google Scholar Irkle, A. et al. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. Nat. Commun. 6, 7495 (2015). Article PubMed Google Scholar Galis, Z. et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res. 75, 181–189 (1994). Article CAS PubMed Google Scholar Alexander, M. R. et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J. Clin. Invest. 122, 70–79 (2012). Article CAS PubMed Google Scholar Libby, P. Mechanisms of acute coronary syndromes and their implications for therapy. N. Engl. J. Med. 368, 2004–2013 (2013). A consideration of the cellular and molecular mechanisms that underlie the acute coronary syndromes. Article CAS PubMed Google Scholar Bentzon, J. F., Otsuka, F., Virmani, R. & Falk, E. Mechanisms of plaque formation and rupture. Circ. Res. 114, 1852–1866 (2014). An authoritative review of the pathological findings that provide insight into the mechanisms of atherogenesis and its thrombotic complications. Article CAS PubMed Google Scholar Libby, P. & Pasterkamp, G. Requiem for the ‘vulnerable plaque’. Eur. Heart J. 36, 2984–2987 (2015). PubMed Google Scholar Pasterkamp, G., den Ruijter, H. M. & Libby, P. Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease. Nat. Rev. Cardiol. 14, 21–29 (2017). Article CAS PubMed Google Scholar Amento, E. P., Ehsani, N., Palmer, H. & Libby, P. Cytokines and growth factors positively and negatively regulate intersitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 11, 1223–1230 (1991). Article CAS Google Scholar Galis, Z., Sukhova, G., Lark, M. & Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493–2503 (1994). Article CAS PubMed PubMed Central Google Scholar Galis, Z., Sukhova, G., Kranzhöfer, R., Clark, S. & Libby, P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. USA 92, 402–406 (1995). Article CAS PubMed PubMed Central Google Scholar Martinod, K. & Wagner, D. D. Thrombosis: tangled up in NETs. Blood 123, 2768–2776 (2014). Article CAS PubMed PubMed Central Google Scholar Franck, G. et al. Roles of PAD4 and NETosis in experimental atherosclerosis and arterial injury: implications for superficial erosion. Circ. Res. 123, 33–42 (2018). Article CAS PubMed PubMed Central Google Scholar Folco, E. J. et al. Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1α and cathepsin G. Arterioscler. Thromb. Vasc. Biol. 38, 1901–1912 (2018). Article CAS PubMed PubMed Central Google Scholar Bevilacqua, M. P., Schleef, R., Gimbrone, M. A. J. & Loskutoff, D. J. Regulation of the fibrinolytic system of cultured human vascular endothelium by IL-1. J. Clin. Invest. 78, 587–591 (1986). Article CAS PubMed PubMed Central Google Scholar van Lammeren, G. W. et al. Time-dependent changes in atherosclerotic plaque composition in patients undergoing carotid surgery. Circulation 129, 2269–2276 (2014). Article PubMed CAS Google Scholar Quillard, T., Franck, G., Mawson, T., Folco, E. & Libby, P. Mechanisms of erosion of atherosclerotic plaques. Curr. Opin. Lipidol. 28, 434–441 (2017). Article CAS PubMed PubMed Central Google Scholar Quillard, T. et al. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur. Heart J. 36, 1394–1404 (2015). Article CAS PubMed PubMed Central Google Scholar Franck, G. et al. Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury via TLR2 in mice: implications for superficial erosion. Circ. Res. 121, 31–42 (2017). Article CAS PubMed PubMed Central Google Scholar Fernandez-Friera, L. et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) study. Circulation 131, 2104–2113 (2015). Article PubMed Google Scholar Doukky, R. et al. Promoting appropriate use of cardiac imaging: no longer an academic exercise. Ann. Intern. Med. 166, 438–440 (2017). Article PubMed Google Scholar Gould, K. L. & Lipscomb, K. Effects of coronary stenoses on coronary flow reserve and resistance. Am. J. Cardiol. 34, 48–55 (1974). Article CAS PubMed Google Scholar Rumberger, J. A. Coronary artery disease: a continuum, not a threshold. Mayo Clin. Proc. 92, 323–326 (2017). Google Scholar Topol, E. J. & Nissen, S. E. Our preoccupation with coronary luminology. The dissociation between clincial and angiographic findings in ischemic heart disease. Circulation 92, 2333–2342 (1995). Article CAS PubMed Google Scholar Tonino, P. A. L. et al. Angiographic versus functional severity of coronary artery stenoses in the fame study. J. Am. Coll. Cardiol. 55, 2816–2821 (2010). Article PubMed Google Scholar Falk, E., Shah, P. K. & Fuster, V. Coronary plaque disruption. Circulation 92, 657–671 (1995). Article CAS PubMed Google Scholar Bittencourt, M. S. et al. Prognostic value of nonobstructive and obstructive coronary artery disease detected by coronary computed tomography angiography to identify cardiovascular events. Circ. Cardiovasc. Imaging. 7, 282–291 (2014). Article PubMed Google Scholar Maddox, T. M. et al. Nonobstructive coronary artery disease and risk of myocardial infarction. JAMA 312, 1754–1763 (2014). Article CAS PubMed PubMed Central Google Scholar Wilson, J. M. & Jungner, Y. G. Principles and practice of mass screening for disease [article in Spanish]. Bol. Oficina Sanit. Panam. 65, 281–393 (1968). CAS PubMed Google Scholar Piepoli, M. F. et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 37, 2315–2381 (2016). Article PubMed PubMed Central Google Scholar US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA 316, 1997–2007 (2016). Article Google Scholar Goff, D. C. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S49–S73 (2014). Article PubMed Google Scholar Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1–S45 (2014). Article PubMed Google Scholar Nasir, K. et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 66, 1657–1668 (2015). Article CAS PubMed Google Scholar Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017). Article CAS PubMed Google Scholar Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017). Article CAS PubMed Google Scholar Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319–1330 (2017). Article CAS PubMed Google Scholar Roth, G. A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1–25 (2017). Article PubMed PubMed Central Google Scholar Heidenreich, P. A. et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123, 933–944 (2011). Article PubMed Google Scholar McConnachie, A. et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur. Heart J. 35, 290–298 (2014). Article CAS PubMed Google Scholar Lloyd-Jones, D. M. et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113, 791–798 (2006). Article PubMed Google Scholar Falaschetti, E. et al. Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. Eur. Heart J. 31, 3063–3072 (2010). Article CAS PubMed PubMed Central Google Scholar Victora, C. G. et al. Maternal and child undernutrition: consequences for adult health and human capital. Lancet 371, 340–357 (2008). Article CAS PubMed PubMed Central Google Scholar Juonala, M. et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N. Engl. J. Med. 365, 1876–1885 (2011). Article CAS PubMed Google Scholar Vedanthan, R. et al. Family-based approaches to cardiovascular health promotion. J. Am. Coll. Cardiol. 67, 1725–1737 (2016). Article PubMed Google Scholar Ference, B. A. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. Curr. Opin. Lipidol. 26, 566–571 (2015). Article CAS PubMed Google Scholar Pahkala, K. et al. Ideal cardiovascular health in adolescence: effect of lifestyle intervention and association with vascular intima-media thickness and elasticity (the Special Turku Coronary Risk Factor Intervention Project for Children [STRIP] study). Circulation 127, 2088–2096 (2013). Article PubMed Google Scholar Koskinen, J. et al. Arterial structure and function after recovery from the metabolic syndrome. The Cardiovascular Risk in Young Finns Study. Circulation 121, 392–400 (2010). Article PubMed Google Scholar Tonetti, M. S. et al. Treatment of periodontitis and endothelial function. N. Engl. J. Med. 356, 911–920 (2007). Article CAS PubMed Google Scholar Baena-Diez, J. M. et al. Association between chronic immune-mediated inflammatory diseases and cardiovascular risk. Heart 104, 119–126 (2017). Article PubMed CAS Google Scholar D’Aiuto, F. et al. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol. 6, 954–965 (2018). Article PubMed Google Scholar D’Aiuto, F. & Deanfield, J. E. Intensive periodontal therapy and type 2 diabetes - Authors’ reply. Lancet Diabetes Endocrinol. 7, 175–176 (2019). Article PubMed Google Scholar Marma, A. K., Berry, J. D., Ning, H., Persell, S. D. & Lloyd-Jones, D. M. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ. Cardiovasc. Qual. Outcomes. 3, 8–14 (2010). Article PubMed Google Scholar Berry, J. D. et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease. The Coronary Artery Risk Development in Young Adults Study and Multi-Ethnic Study of Atherosclerosis. Circulation 119, 382–389 (2009). Article PubMed PubMed Central Google Scholar Patel, R. S. et al. Online self-assessment of cardiovascular risk using the Joint British Societies (JBS3)-derived heart age tool: a descriptive study. BMJ Open 6, e011511 (2016). Article PubMed PubMed Central Google Scholar JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 100 (Suppl. 2), ii1–ii67 (2014). Article CAS Google Scholar Lopez-Gonzalez, A. A. et al. Effectiveness of the heart age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial. Eur. J. Prev. Cardiol. 22, 389–396 (2015). Article Google Scholar Kivipelto, M. et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 5, 735–741 (2006). Article PubMed Google Scholar Gottesman, R. F. et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 71, 1218–1227 (2014). Article PubMed PubMed Central Google Scholar Rovio, S. P. et al. Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns study. J. Am. Coll. Cardiol. 69, 2279–2289 (2017). Article PubMed Google Scholar Ngandu, T. et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385, 2255–2263 (2015). Article PubMed Google Scholar Turakhia, M. P. et al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. Am. Heart J. 207, 66–75 (2019). Article PubMed Google Scholar Wilkins E. W. L. et al. European Cardiovascular Disease Statistics 2017. (European Heart Network, 2017). Moran, A. E. et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation 129, 1483–1492 (2014). Article PubMed PubMed Central Google Scholar Mora, S., Ames, J. M. & Manson, J. E. Low-dose aspirin in the primary prevention of cardiovascular disease: shared decision making in clinical practice. JAMA 316, 709–710 (2016). Article PubMed Google Scholar Mora, S. & Manson, J. E. Aspirin for primary prevention of atherosclerotic cardiovascular disease: advances in diagnosis and treatment. JAMA Intern. Med. 176, 1195–1204 (2016). Article PubMed Google Scholar Dugani, S., Ames, J. M., Manson, J. E. & Mora, S. Weighing the anti-ischemic benefits and bleeding risks from aspirin therapy: a rational approach. Curr. Atheroscler. Rep. 20, 15 (2018). Article PubMed CAS Google Scholar Ridker, P. M. Should aspirin be used for primary prevention in the post-statin era? N. Engl. J. Med. 379, 1572–1574 (2018). Article PubMed Google Scholar Raber, I. et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 393, 2155–2167 (2019). Article PubMed Google Scholar Betsholtz, C. et al. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. Nature 320, 695–699 (1986). Article CAS PubMed Google Scholar Chow, C. K. et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 121, 750–758 (2010). Article PubMed Google Scholar Law, M. R., Morris, J. K. & Wald, N. J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009). Article CAS PubMed PubMed Central Google Scholar Duckworth, W. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129–139 (2009). Article CAS PubMed Google Scholar Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010). Article CAS Google Scholar Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532–2561 (2016). Article CAS PubMed Google Scholar Ridker, P. M. What works and in whom? A simple, easily applied, evidence-based approach to guidelines for statin therapy. Circ. Cardiovasc. Qual. Outcomes. 5, 592–593 (2012). Article PubMed Google Scholar Ridker P. M., Libby P. and Buring J. E. in Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 10th Edition (ed. Braunwald, E.) 891–933 (Saunders, 2014). Grundy, S. M. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139, e1082–e1143 (2019). PubMed Google Scholar Di Angelantonio, E. et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009). Article PubMed Google Scholar Saely, C. H., Rein, P. & Drexel, H. Combination lipid therapy in type 2 diabetes. N. Engl. J. Med. 363, 692 (2010). author reply 694–695. Article Google Scholar Department of Health and Human Services. Food and Drug Aministration. AbbVie Inc. et al. Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Fed. Regist. 81, 22612–22613 (2016). Google Scholar Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010). Article CAS Google Scholar Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1–S45 (2014). Article PubMed Google Scholar [No authors listed].The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251, 365–374 (1984). Article Google Scholar Hammersley, D. & Signy, M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther. Adv. Chronic Dis. 8, 4–11 (2017). Article CAS PubMed Google Scholar Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387–2397 (2015). Article CAS PubMed Google Scholar Robinson, J. G. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489–1499 (2015). Article CAS PubMed Google Scholar Sabatine, M. S. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500–1509 (2015). Article CAS PubMed Google Scholar Nicholls, S. J. et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial. JAMA 316, 2373–2384 (2016). Article CAS PubMed Google Scholar Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017). Article CAS PubMed Google Scholar Ridker, P. M. et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N. Engl. J. Med. 376, 1527–1539 (2017). Article CAS PubMed Google Scholar Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 376, 1430–1440 (2017). Article CAS PubMed Google Scholar Giugliano, R. P. et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390, 1962–1971 (2017). Article CAS PubMed Google Scholar Landmesser, U. et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur. Heart J. 38, 2245–2255 (2017). A masterful review of an important innovation in anti-atherosclerotic therapy with an emphasis on its practical application. CAS PubMed Google Scholar Annemans, L., Packard, C. J., Briggs, A. & Ray, K. K. ‘Highest risk-highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. Eur. Heart J. 39, 2546–2550 (2018). Article PubMed Google Scholar Sabatine, M. S. et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease. Circulation 138, 756–766 (2018). Article CAS PubMed Google Scholar Bhatt, D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 380, 11–22 (2018). Article PubMed Google Scholar Antithrombotic Trialists’ Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71–86 (2002). Article Google Scholar Zheng, S. L. & Roddick, A. J. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA 321, 277–287 (2019). Article CAS PubMed PubMed Central Google Scholar Roffi, M. et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur. Heart J. 37, 267–315 (2016). Article CAS PubMed Google Scholar Ridker, P. M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017). Article CAS PubMed Google Scholar Bevilacqua, M. P., Pober, J. S., Majeau, G. R., Cotran, R. S. & Gimbrone, M. A. Jr. Interleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J. Clin. Invest. 76, 2003–2011 (1985). Article CAS PubMed PubMed Central Google Scholar Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019). Article CAS PubMed Google Scholar Nissen S. E. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl. J. Med. 375, 2519–2529 (2016). Ricciotti, E. & FitzGerald, G. A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 986–1000 (2011). Article CAS PubMed PubMed Central Google Scholar Benner JS, G. R., Mogun, H., Neumann, P. J., Weinstein, M. C. & Avorn, J. Long-term persistence in use of statin therapy in elderly patients. JAMA 288, 455–461 (2002). Article PubMed Google Scholar Kim, M. C. et al. Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction. Am. J. Cardiol. 115, 1–7 (2015). Article PubMed Google Scholar Zhang, H., Plutzky, J., Shubina, M. & Turchin, A. Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study. Ann. Intern. Med. 167, 221–227 (2017). Article PubMed Google Scholar Stroes, E. S. et al. Statin-associated muscle symptoms: impact on statin therapy–European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012–1022 (2015). Article CAS PubMed PubMed Central Google Scholar Newman, C. B. et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 39, e38–e81 (2019). Article CAS PubMed Google Scholar Vaishnava, P. & Lewis, E. F. Assessment of quality of life in severe heart failure. Curr. Heart Fail. Rep. 4, 170–177 (2007). Article PubMed Google Scholar Mark, D. B. Assessing quality-of-life outcomes in cardiovascular clinical research. Nat. Rev. Cardiol. 13, 286–308 (2016). Article PubMed Google Scholar Muhammad, I., He, H. G., Kowitlawakul, Y. & Wang, W. Narrative review of health-related quality of life and its predictors among patients with coronary heart disease. Int. J. Nurs. Pract. 22, 4–14 (2016). Article PubMed Google Scholar Lewis, E. F. et al. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC Heart Fail. 2, 159–165 (2014). Article PubMed Google Scholar Thomas, S. B. et al. Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial. Am. J. Public Health 100 (Suppl. 1), S269–S276 (2010). Article PubMed PubMed Central Google Scholar Sajobi, T. T. et al. Trajectories of health-related quality of life in coronary artery disease. Circ. Cardiovasc. Qual. Outcomes 11, e003661 (2018). Article PubMed Google Scholar De Smedt, D. et al. Validity and reliability of three commonly used quality of life measures in a large European population of coronary heart disease patients. Int. J. Cardiol. 167, 2294–2299 (2013). Article PubMed Google Scholar Hlatky, M. A. et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am. J. Cardiol. 64, 651–654 (1989). Article CAS PubMed Google Scholar Kroenke, K., Spitzer, R. L. & Williams, J. B. The PHQ-9: validity of a brief depression severity measure. J. Gen. Intern. Med. 16, 606–613 (2001). Article CAS PubMed PubMed Central Google Scholar Kulik, A. Quality of life after coronary artery bypass graft surgery versus percutaneous coronary intervention: what do the trials tell us? Curr. Opin. Cardiol. 32, 707–714 (2017). Article PubMed Google Scholar Gomes-Neto, M. et al. High-intensity interval training versus moderate-intensity continuous training on exercise capacity and quality of life in patients with coronary artery disease: a systematic review and meta-analysis. Eur. J. Prev. Cardiol. 24, 1696–1707 (2017). Article PubMed Google Scholar Allen, J. K. & Dennison, C. R. Randomized trials of nursing interventions for secondary prevention in patients with coronary artery disease and heart failure: systematic review. J. Cardiovasc. Nurs. 25, 207–220 (2010). Article PubMed Google Scholar De Smedt, D. et al. The association between self-reported lifestyle changes and health-related quality of life in coronary patients: the EUROASPIRE III survey. Eur. J. Prev. Cardiol. 21, 796–805 (2014). Article PubMed Google Scholar Thomas L. The Lives of a Cell. New York: Penguin Books; 1974: 31–36. Libby, P., Pasterkamp, G., Crea, F. & Jang, I. K. Reassessing the mechanisms of acute coronary syndromes. Circ. Res. 124, 150–160 (2019). Article CAS PubMed PubMed Central Google Scholar Which agent would a nurse identify as a cholesterol absorption inhibitor?Cholesterol absorption inhibitor - ezetimibe
Ezetimibe (Zetia) is a prescription medication used to help lower cholesterol in the blood. It can be used alone or with other cholesterol-lowering drugs such as Lipitor and Zocor.
What should the nurse suggest to assist a client to improve his cholesterol levels?Increase fruits, vegetables, whole grains, and fish. 3. Educate on statin medication. Patients who cannot reduce their cholesterol levels through lifestyle changes require statin medication.
Which agent would a nurse identify as a cholesterol absorption inhibitor quizlet?Ezetimibe is a cholesterol absorption inhibitor and comes in tablet form. The other two options are bile acid sequestrants, but should not be taken with carbonated beverages. The carbonation interferes with the absorption of the drug. The patient asks the nurse what atorvastatin (Lipitor), newly prescribed, will do.
How should the nurse instruct the client to take his lovastatin?Swallow the extended-release tablets whole; do not split, chew, or crush them. Your doctor may start you on a low dose of lovastatin and gradually increase your dose, not more than once every 4 weeks.
|
The formation of atheromas in blood vessels precedes the signs and symptoms of
zusammenhängende Posts
Urheberrechte © © 2024 toptenid.com Inc.
